SPDR Series Trust SPDR S&P Biotech ETF

No trades

See on Supercharts

Overview

Analysis News Ideas Discussions Technicals Seasonals Options

XBI chart

Full chart

Key stats

Assets under management (AUM)

‪6.10 B‬ USD

Fund flows (1Y)

‪−710.43 M‬ USD

Dividend yield (indicated)

0.15%

Discount/Premium to NAV

−0.03%

Shares outstanding

‪69.42 M‬

Expense ratio

0.35%

About SPDR Series Trust SPDR S&P Biotech ETF

Issuer

State Street Corp.

Brand

SPDR

Home page

us.spdrs.com

Inception date

Jan 31, 2006

Structure

Open-Ended Fund

Index tracked

S&P Biotechnology Select Industry

Management style

Passive

Distributes

Capital Gains

Max ST capital gains rate

39.60%

Max LT capital gains rate

20.00%

Tax on distributions

Qualified dividends

XBI provides exposure to US biotech stocks, as defined by GICS, from a universe that invests across the market-cap spectrum. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market-cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap. The index is rebalanced quarterly.